Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil and Beraprost in Chronic Renal Failure
NCT03682952Phase 4
Key facts
- Status
- Unknown
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Countries
- 1
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Conditions
- chronic kidney disease (CKD)
01
Overview
Phase 4, open-label trial of Alprostadil Liposomes for Injection and beraprost in chronic kidney disease (CKD), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Nailfold microcirculation morphological integral at 14 weeks. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-label
03
Endpoints
Primary
Nailfold microcirculation morphological integral
Beyond the preview
Go deeper on NCT03682952.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682952.